In this study, we will dissect the mechanism underlying the specificity of SBE in repressing SHH signaling pathway to block NSCLC progression and metastasis, as well as validate the efficacy of SBE as a potential therapeutic drug candidate for NSCLC patients. The gene discussed is SHH; the disease is non-small cell lung carcinoma.